Regeneron Pharmaceuticals INC
At a glance
Employees500+
In business sinceNot reported
HeadquartersTarrytown, NY
US patents1,376
SAM.gov UEIN3F9MH7E6HD6
CAGE code544P9
Incorporated inNY
LEI549300RCBFWIRX3HYQ56
Supplier designations
For Profit OrganizationManufacturer of Goods
Self-certified by the company in its SAM.gov registration
Patents
1,376 US patents granted 1992–2025, 686 of them in the five years to SEP 2025, including 20 design patents.
Pharmaceuticals 796Biotechnology 326Measurement 175Medical technology 23Computer technology 12
- CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregationUS 12,421,512 · granted SEP 23, 2025
- Polynucleotides encoding anti-glucagon-like peptide 1 receptor (GLP1R) antagonist antibodiesUS 12,421,317 · granted SEP 23, 2025
- CLL-1 targeted immunotherapiesUS 12,421,315 · granted SEP 23, 2025
- Diels-Alder conjugation methodsUS 12,419,963 · granted SEP 23, 2025
- Non-human animals expressing humanized CD3 complexUS 12,419,282 · granted SEP 23, 2025
Newest 5 shown · Granted to Regeneron Pharmaceuticals, INC. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Regeneron Pharmaceuticals INC | Tarrytown | NY | 500+ | LIKELY ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.